Home » Stocks » Anixa Biosciences

Anixa Biosciences, Inc. (ANIX)

Stock Price: $2.80 USD -0.06 (-2.10%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $2.79 -0.01 (-0.36%) Aug 7, 5:12 PM

Stock Price Chart

Key Info

Market Cap 65.86M
Revenue (ttm) n/a
Net Income (ttm) -9.46M
Shares Out 23.52M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $2.80
Previous Close $2.86
Change ($) -0.06
Change (%) -2.10%
Day's Open 2.82
Day's Range 2.77 - 2.87
Day's Volume 61,619
52-Week Range 1.70 - 3.84

More Stats

Market Cap 65.86M
Enterprise Value 60.43M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 23.52M
Float 21.69M
EPS (basic) -0.46
EPS (diluted) -0.46
FCF / Share -0.26
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.32M
Short Ratio 3.11
Short % of Float 6.93%
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.90
Revenue n/a
Operating Income -9.61M
Net Income -9.46M
Free Cash Flow -5.46M
Net Cash 5.43M
Net Cash / Share 0.23
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -87.77%
ROE -173.79%
ROIC -566.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.75*
(212.50% upside)
Low
8.50
Current: $2.80
High
9.00
Target: 8.75
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.251.110.360.309.263.670.390.941.000.73
Revenue Growth-77.53%206.9%20.83%-96.76%152.36%843.12%-58.63%-6.3%37.3%-
Gross Profit0.080.340.260.085.611.680.070.940.970.65
Operating Income-11.89-14.29-6.08-4.51-0.94-5.04-7.92-4.13-5.03-5.25
Net Income-11.65-14.00-5.01-5.02-1.38-9.61-10.08-4.25-7.38-5.18
Shares Outstanding19.7917.6212.208.748.768.717.877.276.675.94
Earnings Per Share-0.59-0.79-0.58-0.57-0.16-1.10-1.25-0.50-1.00-0.75
Operating Cash Flow-4.74-4.27-3.80-3.381.36-2.38-3.19-3.14-0.72-2.41
Capital Expenditures-0.18-0.040.01-0.15-0.05-0.01---0.01-
Free Cash Flow-4.92-4.31-3.78-3.531.31-2.39-3.19-3.14-0.73-2.41
Cash & Equivalents5.845.066.843.246.775.860.900.843.021.09
Total Debt------5.555.035.005.00
Net Cash / Debt5.845.066.843.246.775.86-4.65-4.19-1.98-3.91
Assets6.296.458.815.639.349.065.445.668.6510.05
Liabilities1.481.270.894.644.285.058.766.857.595.45
Book Value5.245.437.920.995.054.01-3.32-1.191.064.60
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anixa Biosciences, Inc.
Country United States
Employees 7
CEO Amit D. Kumar

Stock Information

Ticker Symbol ANIX
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: ANIX
IPO Date January 1, 1987

Description

Anixa Biosciences, Inc., a biotechnology company, develops diagnostics and therapeutics to diagnose, treat, and prevent cancer. The company is developing the Cchek platform, a series of non-invasive blood tests for the early detection of cancer, which is based on the body's immune response to the presence of a malignancy. It is also developing a vaccine against triple negative breast cancer; and chimeric endocrine receptor T-cell technology focused on treating ovarian cancer. Anixa Biosciences, Inc. has a collaboration with Urology San Antonio, P.A. and Idaho Urologic Institute, PA for the development of Cchek, a liquid biopsy technology; and with OntoChem GmbH to develop novel Covid-19 therapeutics. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was founded in 1982 and is based in San Jose, California.